Related Experiment Video
Updated: Mar 20, 2026
10:17
The Tail Suspension Test
Published on: January 28, 2012
83.9K
Leptin serum concentrations are associated with weight gain during lithium augmentation
Roland Ricken1, Sandra Bopp1, Peter Schlattmann2
1Department of Psychiatry and Psychotherapy, Charité University Medicine Berlin, Campus Mitte, Berlin, Germany.
Psychoneuroendocrinology
|May 29, 2016
Summary
Lithium augmentation (LA) for depression may cause weight gain. This study found that leptin levels were positively associated with body mass index (BMI) changes during LA treatment.
Area of Science:
- Psychiatry
- Endocrinology
- Metabolic Research
Background:
- Meta-analyses confirm lithium augmentation (LA) efficacy for major depression.
- Weight gain is a frequent adverse effect associated with LA.
- The proteohormone leptin is implicated in psychopharmacological treatment-induced weight gain.
Purpose of the Study:
- To investigate the association between leptin and body mass index (BMI) during lithium augmentation (LA).
- To explore the role of leptin in weight changes associated with LA in major depressive patients.
Main Methods:
- A prospective cohort study involving 89 acute depressive patients.
- Measurement of leptin serum concentrations and body mass index (BMI) before and after four weeks of LA.
Main Results:
- Linear mixed model analysis revealed a significant positive effect of time (treatment effect of LA) and leptin on BMI.
- Covariates with significant positive effects on BMI included male gender and adiposity.
- Leptin demonstrated a significant positive association with BMI changes during LA.
Conclusions:
- Leptin signaling may play a role in lithium-induced weight gain.
- Further research is needed to confirm the specificity of leptin's effect on BMI during LA, ideally with a control group.
More Related Videos
Related Concept Videos
01:24Mania and Antimanic Drugs: Overview
745
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
745
01:21Drug Dosing: Obese Patients
333
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
333
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
272
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
272
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
360
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
360
01:16Insulin: Dosing Regimen and Adverse Effects
1.1K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.1K
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
850
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
850